软脉健靶向EphA2/ephrinA1通路调控炎症反应改善动脉粥样硬化
本研究采用ApoE-/-小鼠高脂饮食动脉粥样硬化模型及体外VSMC实验,探讨软脉健(RMJ)通过EphA2/ephrinA1通路调控炎症反应的作用。结果显示RMJ降低血脂、减轻全身炎症、稳定斑块,下调EphA2并上调ephrinA1,抑制VSMC增殖与迁移,且未见肝肾毒性。
要点
- RMJ可降低动脉粥样硬化模型血脂并减轻全身炎症。
- RMJ通过下调EphA2、上调ephrinA1抑制VSMC增殖迁移。
- RMJ在所用模型中未观察到肝肾毒性,安全性较好。
核心结论
- RMJ主要通过调控EphA2/ephrinA1信号通路减轻炎症和VSMC增殖,从而发挥抗动脉粥样硬化作用。
- RMJ疗效结合未观察到肝毒性或肾毒性,提示其作为动脉粥样硬化性心血管病新治疗候选物的潜力。
研究设计与样本
- 研究采用体内ApoE-/-小鼠模型与体外研究相结合的设计。
- ApoE-/-小鼠经高脂饮食诱导动脉粥样硬化后接受不同剂量RMJ治疗。
主要发现
- RMJ治疗显著降低血清脂质水平、减轻全身炎症,并通过增加胶原含量和减少脂质沉积稳定动脉粥样硬化斑块。
- RMJ下调EphA2表达并上调ephrinA1,通过抑制AKT1/ERK1/2信号级联有效抑制VSMC增殖和迁移。
- 治疗小鼠中未观察到肝脏或肾脏毒性。
关键数值与推荐
- 检测指标包括血清脂质水平、炎症细胞因子(TNF-α、IL-6、IL-1β)及斑块形态。
- 采用免疫组化和Western blot分析EphA2/ephrinA1通路调控,体外进行VSMC增殖与迁移实验。
临床怎么用
- RMJ可作为动脉粥样硬化患者调节炎症和VSMC行为的潜在中药复方选择。
- 其作用机制涉及EphA2/ephrinA1及下游AKT1/ERK1/2通路,可作为机制研究方向。
- 在所用模型中未见肝肾毒性,但临床使用仍需按中药合理使用原则评估。
局限性
- 研究为动物与体外实验,临床疗效与安全性尚需进一步研究验证。
- 原文未报告具体剂量、样本量及统计学数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atherosclerosis is a major contributor to global cardiovascular morbidity and mortality, driven by the chronic inflammatory proliferation of vascular smooth muscle cells (VSMCs), which destabilizes atherosclerotic plaques. The EphA2/ephrinA1 signaling pathway plays a critical role in modulating VSMC inflammatory responses, making it an attractive therapeutic target. However, the clinical application of EphA2 inhibitors remains limited due to safety concerns. Ruan Mai Jian (RMJ), a traditional Chinese herbal medicine, has demonstrated potential efficacy in treating atherosclerosis, though its precise mechanisms remain insufficiently characterized. To date, no study has investigated a Chinese medicine compound capable of regulating atherosclerotic inflammatory responses via the EphA2/ephrinA1 pathway. This study aims to determine whether RMJ treats atherosclerosis both in vivo and in vitro by modulating the EphA2/ephrinA1 pathway, while evaluating its potential hepatic and renal toxicity. STUDY DESIGN: A combination of in vivo (ApoE-/- murine model) and in vitro studies was employed to investigate the effects of RMJ on atherosclerotic progression, inflammatory markers, and VSMC function. METHODS: ApoE-/- mice were fed a high-fat diet to induce atherosclerosis and subsequently treated with RMJ at varying doses. Serum lipid levels, inflammatory cytokines (TNF-α, IL-6, IL-1β), and plaque morphology were analyzed. Immunohistochemical and Western blot analyses were performed to assess the modulation of the EphA2/ephrinA1 pathway. VSMC proliferation and migration assays were conducted to evaluate the effects of RMJ on cellular behavior in vitro. RESULTS: RMJ treatment significantly attenuated serum lipid levels, reduced systemic inflammation, and stabilized atherosclerotic plaques by increasing collagen content and decreasing lipid deposition. RMJ downregulated EphA2 expression and upregulated ephrinA1, effectively inhibiting VSMC proliferation and migration through suppression of the AKT1/ERK1/2 signaling cascade. Importantly, no hepatic or renal toxicity was observed in treated mice, indicating a favorable safety profile. CONCLUSION: RMJ demonstrates significant therapeutic potential for the treatment of atherosclerosis, primarily through modulation of the EphA2/ephrinA1 signaling pathway, resulting in reduced inflammation and VSMC proliferation. Its efficacy, combined with the absence of hepatotoxicity or nephrotoxicity, highlights RMJ as a promising candidate for further investigation as a novel therapeutic agent for atherosclerotic cardiovascular disease.
引用
- Zhao X, Zhang H, Wang J, et al. Regulation of inflammatory responses: Harnessing the Ruan Mai Jian targeting of EphA2/ephrinA1 pathway to enhance atherosclerosis amelioration. Phytomedicine. 2025. PMID: 39842373. doi:10.1016/j.phymed.2025.156398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。